Neoadjuvant Treatment Modalities in Esophageal Cancer

Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · Mar 26, 2021

Keywords

ClinConnect Summary

This clinical trial, titled "Neoadjuvant Treatment Modalities in Esophageal Cancer," is investigating different treatment options for patients with esophageal cancer or cancer at the esophagogastric junction. The aim is to find the best combination of treatments, including chemotherapy, radiation therapy, targeted drugs, and immunotherapy, to improve patient outcomes before surgery. Currently, the trial is recruiting participants aged 18 and older who have been diagnosed with specific types of esophageal cancer and have a good chance of recovery.

To qualify for the study, participants should have a confirmed diagnosis of esophageal cancer, be in good overall health, and be able to provide informed consent. They should not have any distant spread of the cancer or other serious health issues. If eligible, participants will receive one of the new treatment combinations and will be closely monitored to see how well it works. This trial is important because it could lead to better treatment options and improved survival rates for patients facing esophageal cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥18 years；
• • Esophageal or Esophagogastric cancer；
• • Histologically proven squamous cell carcinoma or adenocarcinoma in patients staged as I-IVa (AJCC 8th)；
• • Primary treatment performed in Cancer Hospital, Chinese Academy of Medical Sciences；
• • ECOG PS score: 0\~1；
• • Estimated survival time ≥3 months；
• • Normal organ and marrow function as defined below:Hemoglobin: greater than or equal to 100g/L ;Leukocytes: greater than or equal to 4,000 G/L; Neutrophil: greater than or equal to 2,000 G/L; Platelets: greater than or equal to 100,000/mm3 ; Creatinine: less than or equal to 1.5 times the upper limit or CCR greater than or equal to 60 ml/min; AST/ALT: less than or equal to 2.5 times the upper limit; Total bilirubin: less than or equal to 1.5 times the upper limit; INR: less than or equal to 1.5 times the upper limit; APTT: less than or equal to 1.5 times the upper limit; PT: less than or equal to 1.5 times the upper limit；
• • Informed consent；
• Exclusion Criteria:
• • With any distant metastasis out of regional lymphatic drainage or in liver, lung, bone, CNS, etc；
• • Patients with other cancer history in 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer；
• • Existing active infection such as active tuberculosis and hepatitis；
• • History of myocardial infarction within the past 6 months or history of ventricular arrhythmia；
• • Uncontrolled illness including, but not limited to, active infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness History of allergic reactions attributed to paclitaxel, albumin or cisplatin；
• • Participation in other clinical trials currently or within 4 weeks of selection；
• • Pregnant or lactating females；
• • Absence of medical records.